GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.00 at KeyCorp

GoodRx (NASDAQ:GDRX) had its price target cut by KeyCorp from $7.00 to $6.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s target price points to a potential upside of 39.53% from the company’s current price.

Several other equities analysts have also issued reports on GDRX. Mizuho assumed coverage on GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price on the stock. Citigroup reduced their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Morgan Stanley dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Finally, Barclays reduced their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, GoodRx has a consensus rating of “Moderate Buy” and a consensus target price of $8.43.

GoodRx Trading Down 2.5 %

NASDAQ:GDRX traded down $0.11 during trading hours on Wednesday, reaching $4.30. 547,586 shares of the stock were exchanged, compared to its average volume of 1,195,033. GoodRx has a twelve month low of $4.09 and a twelve month high of $9.26. The business has a 50-day moving average of $4.83 and a two-hundred day moving average of $6.62. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -143.33, a PEG ratio of 3.43 and a beta of 1.27. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Institutional Trading of GoodRx

A number of institutional investors have recently bought and sold shares of the business. ClariVest Asset Management LLC lifted its position in shares of GoodRx by 27.4% during the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock worth $1,527,000 after buying an additional 42,097 shares during the last quarter. American Century Companies Inc. purchased a new stake in GoodRx in the second quarter valued at $18,183,000. Cornercap Investment Counsel Inc. boosted its stake in GoodRx by 1.7% in the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after acquiring an additional 1,266 shares in the last quarter. Plato Investment Management Ltd acquired a new position in GoodRx in the second quarter valued at $43,000. Finally, XTX Topco Ltd grew its holdings in shares of GoodRx by 42.4% during the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after purchasing an additional 8,801 shares during the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.